Management of antipsychotic-induced hyperprolactinemia
Mental Health Clinician · 2016-07 · 6 (4) · 185-190
DOI: 10.9740/mhc.2016.07.185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Clinician, 2016-07. Verfasst von Ashley Tewksbury und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacist, Clinical Specialist Psychiatry, Lutheran Hospital, Cleveland Clinic, Cleveland, Ohio, tewksba@ccf.org. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Antipsychotics represent a large portion of the psychotropics that may induce hyperprolactinemia. Clinical psychiatric pharmacists must be adept in stratifying the relative risk of hyperprolactinemia among psychotropics, identifying patient risk factors, recognizing differential diagnoses, and recommending therapeutic alternatives and treatment strategies. High-potency, typical antipsychotics are more likely to elevate prolactin although exceptions to the rule exist.
Methods
A literature search of PubMed and Google Scholar was performed to identify English language articles on the treatment of antipsychotic-induced hyperprolactinemia in humans. Methodological rigor is summarized for compiled studies in addition to feasibility and limitations of application to clinical practice.
Results
There is an absence of robust evidence for the management of antipsychotic-induced hyperprolactinemia. Among the pharmacological treatments studied, aripiprazole (switching or augmentation) possessed the strongest evidence. Pharmacological treatments with less evidence encompassed dose reduction, switching to lower potency antipsychotics, and adding dopamine agonists. To date, no head-to-head studies have been published on the above approaches.
Discussion
Atypical antipsychotics with low affinity for dopamine (D2) receptors, such as olanzapine, are logical alternatives for the patient experiencing drug-induced hyperprolactinemia. When augmentation is clinically preferred to switching, a viable option is the addition of a full or partial dopamine agonist, such as bromocriptine or aripiprazole, respectively. Patient-specific risk of psychiatric decompensation and the severity of symptomatic hyperprolactinemia should be weighed when formulating treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacist, Clinical Specialist Psychiatry, Lutheran Hospital, Cleveland Clinic, Cleveland, Ohio, tewksba@ccf.org.
- PharmD Candidate, The Ohio State University College of Pharmacy, Columbus, Ohio.
Zitieren
APA
Tewksbury, A., & Olander, A. (2016). Management of antipsychotic-induced hyperprolactinemia. Mental Health Clinician, 6(4), 185-190. https://doi.org/10.9740/mhc.2016.07.185
Vancouver
Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Mental Health Clinician. 2016;6(4):185-190. doi:10.9740/mhc.2016.07.185
BibTeX
@article{Tewksbury2016,
author = {Tewksbury, Ashley and Olander, Amy},
title = {Management of antipsychotic-induced hyperprolactinemia},
journal = {Mental Health Clinician},
year = {2016},
volume = {6},
number = {4},
pages = {185--190},
doi = {10.9740/mhc.2016.07.185}
}
EUVIMED